< Terug naar vorige pagina


A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020)

Tijdschriftbijdrage - Tijdschriftartikel

Tijdschrift: Trials
Issue: 1
Volume: 21
Aantal pagina's: 1
Jaar van publicatie:2020